No. (%) | |||||
Characteristic | Overall (n=21) | Cohort 1: SBRT 8GyX5+nivolumab (HPV+) | Cohort 2: SBRT 8GyX3 + Nivolumab (HPV+) | Cohort 3: SBRT 8GyX3 (HPV+) | Cohort 4: SBRT 8GyX3+nivolumab (HPV−) |
Age, median (range), years | 62.8 (50.1–76.0) | 60.6 (50.1–75.5) | 68.4 (61.0–76.4) | 60.5 (53.1–66.4) | 62.2 (50.1–69.4) |
Sex | |||||
Male | 19 (90.5) | 5 (100) | 5 (100) | 5 (83.3) | 4 (80.0) |
Female | 2 (9.5) | 0 | 0 | 1 (16.7) | 1 (20.0) |
Smoker | |||||
No | 11 (52.4) | 4 (80.0) | 1 (20.0) | 5 (83.3) | 1 (20.0) |
Former, ≤10 packs year | 3 (14.3) | 1 (20.0) | 1 (20.0) | 1 (16.7) | 0 |
Former, ≥10 packs year | 7 (33.3) | 0 | 3 (60.0) | 0 | 4 (80.0) |
Primary tumor site | |||||
Oropharynx | 15 (71.4) | 4 (80.0) | 4 (80.0) | 6 (100) | 1 (20.0) |
Oral cavity | 2 (9.5) | 0 | 0 | 0 | 2 (40.0) |
Larynx | 2 (9.5) | 0 | 0 | 0 | 2 (40.0) |
Unknown primary | 2 (9.5) | 1 (20.0) | 1 (20.0) | 0 | 0 |
Pretreatment clinical T-stage | |||||
X | 1 (4.8) | 1 (20.0) | 0 | 0 | 0 |
0 | 2 (9.5) | 1 (20.0) | 1 (20.0) | 0 | 0 |
1 | 4 (19.0) | 0 | 1 (20.0) | 2 (33.3) | 1 (20.0) |
2 | 9 (42.9) | 3 (60.0) | 3 (60.0) | 3 (50.0) | 0 |
3 | 1 (4.8) | 0 | 0 | 1 (16.7) | 0 |
4A | 4 (19.0) | 0 | 0 | 0 | 4 (80.0) |
Pretreatment clinical N-stage | |||||
N0 | 2 (9.5) | 0 | 0 | 1 (16.7) | 1 (20.0) |
N1 | 16 (76.2) | 5 (100.0) | 5 (100.0) | 5 (83.3) | 1 (20.0) |
N2c | 2 (9.5) | 0 | 0 | 0 | 2 (40.0) |
N3 | 1 (4.8) | 0 | 0 | 0 | 1 (20.0) |
AJCC overall clinical stage (AJCC, 8th Edition) | |||||
I | 15 (71.4) | 5 (100.0) | 5 (100.0) | 5 (83.3) | 0 |
II | 1 (4.8) | 0 | 0 | 1 (16.7) | 0 |
III | 0 | 0 | 0 | 0 | 0 |
IVA | 4 (19.0) | 0 | 0 | 0 | 4 (80.0) |
IVB | 1 (4.8) | 0 | 0 | 0 | 1 (20.0) |
HPV, human papilloma virus; SBRT, stereotactic body radiation therapy.